Homeostasis model assessment to detect insulin resistance and identify patients at high risk of breast cancer development: National Cancer Institute of Naples experience by Immacolata Capasso et al.
Capasso et al. Journal of Experimental & Clinical Cancer Research 2013, 32:14
http://www.jeccr.com/content/32/1/14RESEARCH Open AccessHomeostasis model assessment to detect insulin
resistance and identify patients at high risk of
breast cancer development: National Cancer
Institute of Naples experience
Immacolata Capasso1*, Emanuela Esposito1, Francesca Pentimalli2, Maurizio Montella3, Anna Crispo3,
Nicola Maurea4, Massimiliano D’Aiuto1, Alfredo Fucito1, Maria Grimaldi3, Ernesta Cavalcanti5, Giuseppe Esposito5,
Giuseppe Brillante1, Sergio Lodato1, Tonino Pedicini6, Giuseppe D’Aiuto1, Gennaro Ciliberto7
and Antonio Giordano2,8,9*Abstract
Background: Metabolic Syndrome (MS) has been correlated to breast carcinogenesis. MS is common in the
general population (34%) and increases with age and body mass index. Although the link between obesity, MS and
hormone related cancer incidence is now widely recognized, the molecular mechanisms at the basis of such
increase are still poorly characterized. A crucial role is supposed to be played by the altered insulin signalling,
occurring in obese patients, which fuels cancer cell growth, proliferation and survival. Therefore we focused
specifically on insulin resistance to investigate clinically the potential role of insulin in breast carcinogenesis.
Methods: 975 patients were enrolled and the association between MS, insulin resistance, and breast cancer was
evaluated. Women were stratified by age and menopausal status. Insulin resistance was measured through the
Homeostasis Model Assessment score (HOMA-IR). The cut off value to define insulin resistance was HOMA-IR≥ 2.50.
Results: Higher prevalence of MS (35%) was found among postmenopausal women with breast cancer compared
to postmenopausal healthy women (19%) [OR 2.16]. A broad range of BMI spanning 19–48 Kg/m2 was calculated.
Both cases and controls were characterized by BMI ≥ 25 Kg/m2 (58% of cases compared to 61% of controls). Waist
circumference >88 cm was measured in 53% of cases - OR 1.58- (95% CI 0.8-2.8) and in 46% of controls.
Hyperinsulinemia was detected in 7% of cases – OR 2.14 (95% CI 1.78-2.99) and only in 3% of controls. HOMA-IR
score was elevated in 49% of cases compared to 34% of controls [OR 1.86], suggesting that insulin resistance can
nearly double the risk of breast cancer development. Interestingly 61% of women operated for breast cancer (cases)
with HOMA-IR ≥ 2.5 presented subclinical insulin resistance with fasting plasma glucose levels and fasting plasma
insulin levels in the normal range. Both android fat distribution and insulin resistance correlated to MS in the
subgroup of postmenopausal women affected by breast cancer.
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Conclusions: Our results further support the hypothesis that MS, in particular insulin resistance and abdominal fat, can
be considered as risk factors for developing breast cancer after menopause. We suggest that HOMA-IR, rather than
fasting plasma glucose and fasting plasma insulin levels alone, could be a valuable tool to identify patients with
subclinical insulin resistance, which could be relevant for primary prevention and for high risk patient screening.
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Metabolic syndrome (MS), characterized by central adi-
posity, insulin resistance, low serum high density lipopro-
tein cholesterol (HDL-C), high serum triglycerides, and
high blood pressure, seems to be in strict correlation to
breast carcinogenesis [1,2]. MS, according to the National
Cholesterol Program (NCEP) Adult Treatment Panel III
(ATP III), can be defined as the presence of at least three
of the following clinical criteria: waist circumference
>88 cm in women, HDL-C <50 mg/dl, blood pressure
≥130/85 mmHg, triglyceride >150 mg/dl and insulin re-
sistance [3]. The prevalence of MS is high in the general
population with approximately 34% of adults meeting the
above-mentioned criteria and increases with age and body
mass index (BMI). In fact, women over 60 years and over-
weight or obese are much more likely to meet the MS cri-
teria [4]. Consistently, post-menopausal women are often
affected by MS and, interestingly, show the highest inci-
dence of breast cancer in the female population [1]. Al-
though many epidemiological studies link obesity and MS
to the increased frequency of many cancer types, the mo-
lecular mechanisms underlying this increased risk are still
poorly characterized. Visceral adipose tissue has multiple
endocrine, metabolic and immunological functions and
has been shown to be central in the MS pathogenesis. MS
is a pro-inflammatory, pro-coagulant state associated with
insulin resistance [5,6]. The increase in adipose tissue
mass, which characterizes MS, can have both direct and
secondary effects favouring tumorigenesis [6]. Obese pa-
tients often develop insulin resistance with various tissues
showing low cell sensitivity to insulin activity. As a conse-
quence, a balancing mechanism stimulates insulin release
resulting in a chronic compensatory hyperinsulinemia. By
continuously stimulating insulin signalling in sensitive tis-
sues, high levels of circulating insulin cause aberrantly in-
creased mitogenic and antiapoptotic effects [7]. Although
the obese state generates peripheral insulin resistance in
many tissues, not all insulin signalling is impaired. In the
diabetic liver, the gluconeogenic pathway becomes insulin
resistant, and insulin-stimulated lipogenesis remains sensi-
tive. Thus, in insulin-resistant patients, specific tissues and
signalling pathways can remain insulin-sensitive and are
exposed to higher than normal levels of insulin signalling.
Initial experiments demonstrated that in human breastcancer cell lines insulin has been shown to promote DNA
synthesis, suggesting a mitogenic effect [6]. When insulin
concentrations are high, insulin — which is structurally
similar to insulin-like growth factor 1 and 2 (IGF1 and
IGF2) — acts also as a growth factor by binding the IGF-
receptors (IGF1R and IGF2R) [8,9]. Moreover, increased
insulin signalling can induce overexpression of the recep-
tors [9]. Consistently, in vitro and in vivo studies have
shown insulin receptor overexpression in breast tissue.
Furthermore, it seems that high insulin levels can alter the
levels of IGF-binding proteins, which regulate the amount
of bioactive insulin or IGFs in the microenvironment,
thereby resulting in impaired insulin signalling [6]. As vari-
ous epidemiological studies associated type 2 diabetes with
increased incidence of various cancer types, including
breast cancer, we wondered what is the specific contribu-
tion of insulin resistance in breast carcinogenesis at the
clinical level [10-12]. To this aim we compared breast can-
cer patients to healthy women in order to assess whether a
correlation exist with MS criteria and, specifically, insulin
resistance measured through Homeostasis Model Assess-
ment (HOMA-IR).
Methods
Enrollment and exclusion criteria
975 women spanning 35–75 years in age have been en-
rolled in our nested case–control observational retrospect-
ive study between 2008 and 2011 (Table 1). 410 women
underwent surgery for breast cancer (cases), whereas 565
were healthy women (controls). Healthy women referred
to National Cancer Institute for the breast cancer screen-
ing program. Women aged over forty had clinical examin-
ation, mammogram and ultrasound. Women under forty
had clinical examination and ultrasound. Cases were pa-
tients with histological diagnosis of breast cancer at age of
recruitment. Controls were patients with completely nega-
tive clinical-instrumental reports and no familial history of
breast or ovarian cancer. None of the controls has devel-
oped a breast cancer till today. In accordance with the
Helsinki Declaration of 1975, after obtaining informed
consent, for each woman anthropometric features were
measured, including weight in kilograms, height in meters,
waist and hip circumference; arterial blood pressure was
taken and venous blood was collected on study entry.




n. % n. %
PRE 229 40.5 124 30.2
POST 336 59.5 286 59.8
Total 565 100 410 100
Age at recruitment
Controls Cases
n. % n. %
< 35 18 3.2 13 3.2
35-44 104 18.4 70 17.1
45-54 217 38.4 99 24.1
55-64 166 29.4 100 24.4
≥65 60 10.6 128 31.2
Total 565 100 410 100
Capasso et al. Journal of Experimental & Clinical Cancer Research 2013, 32:14 Page 3 of 6
http://www.jeccr.com/content/32/1/14Body Mass Index (BMI) (kg/m2) was calculated from
weight and height values and evaluated according to the
World Health Organization classification (<25 kg/m2 =
underweight/normal, ≥25 kg/m2 = overweight/obese). The
waist and hip ratio (WHR) was obtained from waist and
hip circumference, measuring the smallest circumference
of both to discriminate between android and gynoid fat
distribution. Fasting plasma glucose, insulin levels, HDL-C,
triglycerides, were assessed from blood samples. In par-
ticular, fasting plasma glucose, HDL-C and triglycerides
were measured according to the NCEP ATP III criteria.
Blood samples were locally assessed at the central labora-
tory of the National Cancer Institute. Sample collection was
standardized by time at blood withdrawing. Samples were
taken in the early morning hours (between 8.00 and 10.00
A.M.). Fasting plasma glucose assessment was measured by
the COBAS INTEGRA Glucose HK cassette (GLUC2). It
contains an in vitro diagnostic reagent system intended for
use on COBAS INTEGRA systems for the quantitative de-
termination of the glucose concentration in hemolysate.
Electrochemiluminescence immunoassay (ECLIA) applied
on Cobas 6000 was used for insulin concentration measure-
ment. Enzymatic colorimetric test CHOD – POD was
employed for cholesterol dosage. The GPO - POD method
based on the enzymatic determination of glycerol using the
enzyme glycerol phosphate oxidase (GPO) was used for tri-
glycerides determination. Fresh, clear, unhemolyzed serum
was the specimen of choice. The specimen was collected
following the guidelines of NCCLS document H4-A3. Dia-
betes was considered an exclusion criterion. Diabetes was
diagnosed on laboratory determinations with fasting plasma
glucose assessment ≥ 126 mg/dl according to AmericanDiabetes Association guidelines [13]. Fasting plasma
glucose levels in the range between 110 and 126 mg/dl
were considered as hyperglycaemia. Insulin levels were de-
fined in the normal range when between 5 and 25 mcU/ml,
whereas concentrations above 25 mcU/ml were consid-
ered corresponding to hyperinsulinemia.
HOMA – IR and statistical analysis
After data collection, we used the HOMA-IR, Homeostasis
Model Assessment of insulin resistance, to quantify insulin
resistance [14]. The HOMA-IR score was calculated as the
product of the fasting plasma insulin level (mcU/mL) and
the fasting plasma glucose level (mg/dl), divided by 405.
The cut off value to define insulin resistance was HOMA-
IR ≥ 2.50. Patients presenting HOMA-IR ≥ 2.50 were con-
sidered insulin resistant. Chi-squared test and logistic
regression analyses (OR and 95% CI) were used to confirm
the association between MS and breast cancer and to cal-
culate the risk. Regression analyses were adjusted for age,
menopausal status and BMI. Statistical significance was
considered at p < 0.05.
Results
565 healthy women and 410 patients affected by breast
cancer were enrolled between 2008 and 2011 in our
nested case–control observational retrospective study.
Our first end point consisted in updating our previous re-
sults about the association between MS and breast cancer.
Second end point was focusing on insulin resistance that
is the most important feature characterizing MS relation
to cancer. Among the 975 women included in the study
286 cases and 336 controls were defined as menopausal
(mean age 57.6 years) with Odds Ratio of postmenopausal
breast cancer of 1.63 (95% CI 1.09- 1.79). Overall, consid-
ering the 975 women included in the study (age range =
35–75 years) MS prevalence was higher among cases
(27%) than in controls (14%). We did not find significant
differences in MS prevalence between cases and controls
among premenopausal patients, whereas the prevalence of
MS in postmenopausal was 35% for cases OR 2.16 (95%
CI = 0.31 to 0.39) and 19% for controls (95% CI = 0.16 to
0.23). MS was detected in one third of post-menopausal
cases. A broad range of BMI spanning 19–48 Kg/m2 was
calculated. Both cases and controls were characterized by
high BMI (58% of cases compared to 61% of controls).
Waist circumference >88 cm was measured in 53% of
cases - OR 1.58- (95% CI 0.8-2.8) and in 46% of controls.
Hypertriglyceridemia was found in 14% of cases respect
to 9% of controls [OR 1.4]. 27% of cases presented HDL-
C <50 mg/dl compared to 24% of controls [OR 1.09].
High blood pressure was detected in 40% of cases – OR
1.58 (95% CI 0.37-0.47) respect to 30% of controls.
Hyperinsulinemia was detected in 7% of cases – OR 2.14
(95% CI 1.78-2.99) and only in 3% of controls (Table 2).
Table 2 Metabolic variables by case–control status
Cases (410) Controls (565)
N° % N° % p-value
Fasting plasma glucose (mg/dl)
< 110 345 84.1 508 90.0
≥ 110 65 15.9 57 10.0 <0.001
Insulin
0-25 regular 386 94.2 545 96.5
≥ 25 hyperinsulinemia 24 5.8 20 3.5 0.13
High blood pressure
Yes 161 39.4 180 31.8 0.01
No 249 60.6 385 68.2
Tryglicerides
≤150 354 86.4 508 90.4
>150 56 13.6 57 9.6 0.006
HDL-Col
< 50 mg/dL 109 26.5 140 24.9
≥ 50 mg/dl 301 73.5 425 75.1 0.9
WC
≤ 88 cm 195 47.7 304 53.8 0.003
>88 cm 215 52.3 261 46.2
BMI
≤ 25 172 42.0 222 39.3 0.7
>25 238 58.0 343 60.7
WHR
<0.8 99 24.2 118 20.9
≥0.8 311 75.8 447 79.1 0.001
Metabolic syndrome criteria
0-2 301 73.4 484 85.70
3-5 109 26.6 81 14.3 < 0.001
HDL-Chol = HDL-Cholesterol; BMI = Body Mass Index; WC =Waist Circumference; WHR =Waist Hip Ratio.
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(C.I.95% =0.42 to 0.52) respect to 34% of controls
(C.I.95% =0.03 to 0.38), showing a positive trend for
breast cancer patients. Interestingly, 80% of insulin resist-
ant cases were postmenopausal, whereas premenopausal
were only 20% (C.I.95% =0.85 to 0.74 vs 0.33 to 0.7)
(Figure 1).
HOMA-IR and insulin were positively associated to at
least three other MS criteria in 89% of cases compared to
50% of controls. Remarkably, 75% of cases were insulin re-
sistant (HOMA-IR ≥ 2.5) with waist circumference > 88 cm
(Table 3, Figure 2).
Insulin resistant cases and controls have been further
stratified in four subgroups according to fasting plasma
glucose and insulin values. In particular, group 1 had
fasting plasma glucose levels and fasting plasma insulin
levels in the normal range; group 2 had high levels ofboth fasting plasma glucose and fasting plasma insulin;
group 3 had fasting plasma glucose in the normal range
and high levels of fasting plasma insulin; group 4 had
fasting plasma insulin in the normal range and high
levels of fasting plasma glucose. Interestingly, 61% of
women operated for breast cancer (cases) with HOMA-
IR ≥ 2.5 presented fasting plasma glucose levels and
fasting plasma insulin levels in the normal range (group 1).
Only 5% of cases showed high levels of both fasting plasma
glucose and fasting plasma insulin (group 2). 7% were
euglycemic, but plasmatic insulin levels were high (group 3).
27% of patients presented as hyperglycaemic, but insulin
levels were in the normal range (group 4).
Discussion
Our data still confirm the existing linkage between meta-











HOMA-IR  2.5 in cases
HOMA-IR < 2.5 in cases
Figure 1 HOMA- IR as indicator of insulin resistance in pre and
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Figure 2 Histogram comparing insulin resistance and waist
circumference among breast cancer patients. Statistical significance
(P < 0.05) for comparison waist circumference in insulin resistant patients.
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cancer compared to healthy women (19%) [OR 2.16] was
found. No statistical significant difference in pre-
menopausal women was found. Probably, alterations in
metabolic signalling that activate pro-mitotic and anti-
apoptotic pathways are more likely to occur in postmeno-
pausal women. Moreover all MS features were positively,
but weakly associated to breast cancer risk. As expected
from the recent literature, android fat distribution-
consisting in WC >88 cm- was positively associated to MS
and breast cancer more than BMI. Waist circumference
>88 cm was measured in 53% of cases - OR 1.58 (95% CI
0.8-2.8) and in 46% of controls, whereas no differences in
BMI were found between cases and controls. A majority
of prospective studies show breast cancer risk to be higher
in obese postmenopausal women with upper abdominal
adiposity than in those with overall adiposity. The evidence
is more limited and inconsistent in the case of
premenopausal women. Overall adiposity in women ad-
versely affects breast cancer risk mainly by greater expos-
ure of mammary epithelial tissue to endogenous oestrogen
and to pro-inflammatory cytokines. Upper abdominal adi-
posity appears to involve an additional effect related to the
presence of insulin resistance [15]. Waist circumference
measurement reveals to be more accurate than BMI aloneTable 3 HOMA-IR by categories of waist circumference
WAIST CIRCUMFERENCE
HOMA-IR ≤ 88cm >88cm Total
≥ 2.50 51 (25%) 150 (75%) 201
< 2.50 137 (66%) 72 (34%) 209
Total 188 222in breast cancer risk evaluation. Second end point of our
study was to singularly analyze insulin resistance contribu-
tion in determining breast cancer risk. 49% of cases were
insulin resistant respect to 34% of controls [OR 1.86],
suggesting that insulin resistance can nearly double the risk
of breast cancer development. 80% of the insulin resistant
patients were postmenopausal, but the most important as-
pect to consider is that 61% of women operated for breast
cancer (cases) with HOMA-IR ≥ 2.5, and so to be consid-
ered as insulin resistant, presented fasting plasma glucose
levels and fasting plasma insulin levels in the normal range,
whereas 7% of patients were euglycemic, but plasmatic in-
sulin levels were high. Consequently 68% of patients had
levels of fasting plasma glucose in the normal range, and,
similarly, fasting plasma insulin levels were diagnosed as
normal in 88% of cases. Only through the use of HOMA
score were we able to diagnose insulin resistance. These
patients were defined insulin resistant only by using
HOMA-IR score. That means subclinical insulin resistance
can be misunderstood. Last published data by our research
group in 2010 did not consider single features of MS per
se in correlation to breast cancer [1]. Now we have focused
on the association between insulin resistance and breast
cancer and a positive correlation between insulin resistance
and breast cancer patients was found. Both android distri-
bution fat and insulin resistance correlated to MS in the
subgroup of postmenopausal women affected by breast
cancer and were positively and independently associated
with more than three other MS criteria [3,16,17].
Conclusions
Our data, consistently with our previous study, further sup-
port the hypothesis that MS can be considered as a risk
factor for developing breast cancer in postmenopause [1].
We specifically focused on the insulin resistance phenotype,
the condition of chronic hyperinsulinemia to which cells
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tivity [18,19]. Insulin resistance can often be defined as a
subclinical condition. Consistently, most of our patients
(68%) had levels of fasting plasma glucose in the normal
range, and, interestingly, only through the use of HOMA
score we classified them as insulin resistant. Similarly,
fasting plasma insulin levels were diagnosed as normal in
88% of cases. These patients were identified as insulin re-
sistant only by means of the HOMA score. HOMA-IR
is widely-used in epidemiologic studies as a measure
of insulin resistance, and has been shown to reflect
euglycemic clamp insulin resistance more accurately than
fasting insulin levels alone. In conclusion, our experience
suggests that insulin resistance and abdominal fat (more
than BMI alone) represent the most important criteria of
MS on which primary prevention should be concentrated.
Interestingly, Homeostasis Model Assessment of insulin
resistance promises to be a valuable tool for primary pre-
vention, particularly for patients with subclinical insulin
resistance, presenting fasting plasma glucose levels and
fasting plasma insulin levels in the normal range. Our
findings suggest that HOMA-IR could be useful in screen-
ing patients at higher risk of developing breast cancer.
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